ArticleCancer immunology, immunotherapy : CII2015

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.

Balaji Balasa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.